Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

Open to people ages 18 years and up

• Must have relapsed or refractory multiple myeloma (RRMM) after having received prior lines of anti-myeloma treatments.
• Measurable disease as defined by one of the following: abnormal serum or M-protein levels; abnormal serum free light chain (FLC) assay; ≥ 30% clonal plasma cells in the bone marrow aspirate or biopsy sample
• Evidence of cell membrane CD38 expression as determined by immunohistochemistry (IHC) analysis ofbone marrow biopsy or extramedullary plasmacytoma
• Pulse oximetry ≥ 92% on room air
• Have a life expectancy ≥ 12 weeks
• Be willing and able to comply with the study schedule and all study requirements
• Willing to follow contraception guidelines

• Previous treatment with any systemic therapy for multiple myeloma within 14 days prior to start of study dose
• Treatment with any cellular therapy within 8 weeks prior to start of study dose
• Have any unresolved toxicity ≥ Grade 2 from previous anticancer therapies
• A history of brain metastasis or spinal cord compression
• Has an ECOG performance status (PS) ≥ 3
• Has received allogeneic hematopoietic stem cell transplantation (HSCT) within 6 months, has active graft-versus-host disease (GvHD) following transplant, or is currently receiving immunosuppressive therapy following transplant
• Has any clinically significant low baseline lab results for hemoglobin, platelet counts, and neutrophil counts at screening unless resulting from underlying RRMM
• Has any clinically significant elevated baseline lab results for serum creatinine, AST or β2 microglobulin
• Abnormal INR or aPTT, unless on a stable dose of an anticoagulant
• Has known HIV or acquired immunodeficiency syndrome-related illness, acute or history of chronic hepatitis B or C
• Is currently pregnant or breast feeding or planning on either during the study.
• Has an active bacterial, viral, or fungal infection
• Has active plasma cell leukemia
• Has extramedullary plasmacytoma(s)
• Has any significant medical condition, abnormality, or psychiatric illness that would prevent study participation
• Has left ventricular ejection fraction (LVEF) < 40%
• Has second primary malignancies (SPMs) in addition to multiple myeloma if the SPM has required therapy within the last 3 years or is not in complete remission
• Has any additional clinical history of the CNS or cardiovascular disease that would place the patient at an unacceptable risk if the patient participates in the study